Sunshine Biopharma Inc. has announced a significant regulatory milestone, securing Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary. This approval allows Sunshine Biopharma to enter the Canadian pharmaceutical market with domperidone, a move expected to expand its commercial reach and validate its track record of revenue-generating execution. The opportunity is notable, as Canada represents nearly 17% of the North American domperidone market, translating to a $200 million-plus segment. No other organizations were mentioned as recipients of this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1092777) on October 28, 2025, and is solely responsible for the information contained therein.